JP2000504327A5 - - Google Patents

Download PDF

Info

Publication number
JP2000504327A5
JP2000504327A5 JP1997526917A JP52691797A JP2000504327A5 JP 2000504327 A5 JP2000504327 A5 JP 2000504327A5 JP 1997526917 A JP1997526917 A JP 1997526917A JP 52691797 A JP52691797 A JP 52691797A JP 2000504327 A5 JP2000504327 A5 JP 2000504327A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997526917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000504327A (ja
Filing date
Publication date
Priority claimed from US08/591,332 external-priority patent/US5770700A/en
Application filed filed Critical
Publication of JP2000504327A publication Critical patent/JP2000504327A/ja
Publication of JP2000504327A5 publication Critical patent/JP2000504327A5/ja
Withdrawn legal-status Critical Current

Links

JP9526917A 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方 Withdrawn JP2000504327A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/591,332 1996-01-25
US08/591,332 US5770700A (en) 1996-01-25 1996-01-25 Liquid factor IX formulations
PCT/US1997/000747 WO1997026909A1 (en) 1996-01-25 1997-01-09 Highly concentrated, lyophilized, and liquid factor ix formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2006141684A Division JP2006257099A (ja) 1996-01-25 2006-05-22 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2007180835A Division JP4879104B2 (ja) 1996-01-25 2007-07-10 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Publications (2)

Publication Number Publication Date
JP2000504327A JP2000504327A (ja) 2000-04-11
JP2000504327A5 true JP2000504327A5 (enExample) 2004-10-28

Family

ID=24366077

Family Applications (4)

Application Number Title Priority Date Filing Date
JP9526917A Withdrawn JP2000504327A (ja) 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方
JP2006141684A Pending JP2006257099A (ja) 1996-01-25 2006-05-22 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2007180835A Expired - Lifetime JP4879104B2 (ja) 1996-01-25 2007-07-10 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2010106673A Withdrawn JP2010189433A (ja) 1996-01-25 2010-05-06 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006141684A Pending JP2006257099A (ja) 1996-01-25 2006-05-22 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2007180835A Expired - Lifetime JP4879104B2 (ja) 1996-01-25 2007-07-10 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2010106673A Withdrawn JP2010189433A (ja) 1996-01-25 2010-05-06 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Country Status (8)

Country Link
US (1) US5770700A (enExample)
EP (1) EP0876155B1 (enExample)
JP (4) JP2000504327A (enExample)
AT (1) ATE270557T1 (enExample)
AU (1) AU726498B2 (enExample)
CA (1) CA2241319A1 (enExample)
DE (1) DE69729786T2 (enExample)
WO (1) WO1997026909A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP3581660B2 (ja) 1999-04-30 2004-10-27 ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー 潜伏ウイルスの再活性化を予防しウイルスの複製を制御するための方法
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
CN1606452A (zh) * 2001-12-21 2005-04-13 诺沃娜第克公司 修饰的因子ⅶ多肽的液体组合物
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
KR20050013148A (ko) 2002-06-21 2005-02-02 노보 노르디스크 에이/에스 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
CN1780638B (zh) 2003-05-23 2010-04-14 诺和诺德医疗保健公司 氧化硅涂层玻璃作为容器内壁材料的用途及以该材料作内壁的容器
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
ATE507822T1 (de) 2003-12-19 2011-05-15 Novo Nordisk Healthcare Ag Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
EP1755652B1 (en) 2004-03-19 2010-11-24 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
GT200600033A (es) * 2005-01-28 2006-10-25 Formulaciones liquidas estabilizadas de polipeptido
ATE490343T1 (de) * 2005-06-30 2010-12-15 Ge Healthcare Bio Sciences Nachweisverfahren für die genexpression
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN104434770A (zh) 2006-06-16 2015-03-25 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8449520B2 (en) * 2007-03-19 2013-05-28 HemCon Medical Technologies Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
RU2469739C2 (ru) 2007-04-26 2012-12-20 БАЙЕР ХЕЛСКЕА ЛЛСи Стабилизация жидких растворов рекомбинантного белка для хранения в замороженном состоянии
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009129101A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AR076640A1 (es) 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
JP2013520480A (ja) * 2010-02-24 2013-06-06 アレコー リミテッド 第ｉｘ因子の安定組成物
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP6553020B2 (ja) * 2013-03-15 2019-07-31 ジーピービー デット ホールディングス トゥー エルエルシー アレルギー及び自己免疫疾患に関する診断分析を行うための自動化された免疫分析計システム
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN114127501B (zh) 2019-03-14 2023-02-17 泰尔茂比司特生物技术有限公司 多部分冻干容器及使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
IT1171737B (it) * 1983-10-10 1987-06-10 Vamatex Spa Gancio per la guida di nastri portapinze all'interno del passo di telai di tessitura e complesso di guida con esso realizzabile
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4952675A (en) * 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
AU5864086A (en) * 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
JP2715104B2 (ja) * 1988-08-18 1998-02-18 株式会社ミドリ十字 トロンビン乾燥製剤
DE3828009A1 (de) * 1988-08-18 1990-02-22 Wolfgang D Zapp Rahmen aus strangprofilen
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
JP2722143B2 (ja) * 1991-09-03 1998-03-04 株式会社ミドリ十字 トリプシンインヒビター含有凍結乾燥製剤
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JP3537440B2 (ja) * 1993-12-17 2004-06-14 持田製薬株式会社 可溶性トロンボモジュリンを長期保存安定化させる方法
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)
JP2000500184A5 (enExample)